Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults

P. Durando, D. Fenoglio, A. Boschini, F. Ansaldi, G. Icardi, L. Sticchi, A. Renzoni, P. Fabbri, A. Ferrera, A. Parodi, B. Bruzzone, G. Gabutti, A. Podda, G. Del Giudice, E. Fragapane, F. Indiveri, P. Crovari, R. Gasparini

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The objective of this study was to evaluate and compare both the safety and tolerability and the humoral and cell-mediated immune responses for two influenza virus subunit vaccines, one with MF59 adjuvant (Fluad) and one without an adjuvant (Agrippal), in healthy and in human immunodeficiency virus type 1 (HIV-1)-infected adult individuals. To achieve this aim, an open, randomized, comparative clinical trial was performed during the 2005-2006 season. A total of 256 subjects were enrolled to receive one dose of vaccine intramuscularly. Blood samples were taken at the time of vaccination and at 1 and 3 months postvaccination. A good humoral antibody response was detected for both vaccines, meeting all the criteria of the Committee for Medical Products for Human Use. After Beyer's correction for prevaccination status, Fluad exhibited better immuno-genicity than Agrippal, as shown from the analysis of the geometric mean titers, with significant differences for some virus strains; however, no definitive conclusions on the clinical significance of such results can be drawn, because the method used to estimate antibody response is currently nonstandard for influenza virus vaccines. Significant induction of an antigen-specific CD4+ T-lymphocyte proliferative response was detected at all time points after immunization, for both the vaccines, among HIV-1-seronegative subjects. This was different from what was observed for HIV-1-infected individuals. In this group, significance was not reached at 30 days postvaccination (T30) for those immunized with Agrippal. Also when data were compared between treatment groups, a clear difference in the response at T30 was observed in favor of Fluad (P = 0.0002). The safety profiles of both vaccines were excellent. For HIV-1-infected individuals, no significant changes either in viremia or in the CD4+ cell count were observed at any time point. The results showed good safety and immunogenicity for both vaccines under study for both uninfected and HIV-1-infected adults, confirming current recommendations for immunization of this high-risk category.

Original languageEnglish
Pages (from-to)253-259
Number of pages7
JournalClinical and Vaccine Immunology
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Subunit Vaccines
Influenza Vaccines
Viruses
HIV-1
Safety
Vaccines
Immunization
Antibody Formation
CD4 Antigens
Viremia
CD4 Lymphocyte Count
T-cells
Antibodies
Vaccination
Randomized Controlled Trials
MF59 oil emulsion
T-Lymphocytes
Blood
Antigens

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)
  • Medicine(all)

Cite this

Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. / Durando, P.; Fenoglio, D.; Boschini, A.; Ansaldi, F.; Icardi, G.; Sticchi, L.; Renzoni, A.; Fabbri, P.; Ferrera, A.; Parodi, A.; Bruzzone, B.; Gabutti, G.; Podda, A.; Del Giudice, G.; Fragapane, E.; Indiveri, F.; Crovari, P.; Gasparini, R.

In: Clinical and Vaccine Immunology, Vol. 15, No. 2, 02.2008, p. 253-259.

Research output: Contribution to journalArticle

Durando, P, Fenoglio, D, Boschini, A, Ansaldi, F, Icardi, G, Sticchi, L, Renzoni, A, Fabbri, P, Ferrera, A, Parodi, A, Bruzzone, B, Gabutti, G, Podda, A, Del Giudice, G, Fragapane, E, Indiveri, F, Crovari, P & Gasparini, R 2008, 'Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults', Clinical and Vaccine Immunology, vol. 15, no. 2, pp. 253-259. https://doi.org/10.1128/CVI.00316-07
Durando, P. ; Fenoglio, D. ; Boschini, A. ; Ansaldi, F. ; Icardi, G. ; Sticchi, L. ; Renzoni, A. ; Fabbri, P. ; Ferrera, A. ; Parodi, A. ; Bruzzone, B. ; Gabutti, G. ; Podda, A. ; Del Giudice, G. ; Fragapane, E. ; Indiveri, F. ; Crovari, P. ; Gasparini, R. / Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. In: Clinical and Vaccine Immunology. 2008 ; Vol. 15, No. 2. pp. 253-259.
@article{86fb14164e284c56a6f40e8dc4689acb,
title = "Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults",
abstract = "The objective of this study was to evaluate and compare both the safety and tolerability and the humoral and cell-mediated immune responses for two influenza virus subunit vaccines, one with MF59 adjuvant (Fluad) and one without an adjuvant (Agrippal), in healthy and in human immunodeficiency virus type 1 (HIV-1)-infected adult individuals. To achieve this aim, an open, randomized, comparative clinical trial was performed during the 2005-2006 season. A total of 256 subjects were enrolled to receive one dose of vaccine intramuscularly. Blood samples were taken at the time of vaccination and at 1 and 3 months postvaccination. A good humoral antibody response was detected for both vaccines, meeting all the criteria of the Committee for Medical Products for Human Use. After Beyer's correction for prevaccination status, Fluad exhibited better immuno-genicity than Agrippal, as shown from the analysis of the geometric mean titers, with significant differences for some virus strains; however, no definitive conclusions on the clinical significance of such results can be drawn, because the method used to estimate antibody response is currently nonstandard for influenza virus vaccines. Significant induction of an antigen-specific CD4+ T-lymphocyte proliferative response was detected at all time points after immunization, for both the vaccines, among HIV-1-seronegative subjects. This was different from what was observed for HIV-1-infected individuals. In this group, significance was not reached at 30 days postvaccination (T30) for those immunized with Agrippal. Also when data were compared between treatment groups, a clear difference in the response at T30 was observed in favor of Fluad (P = 0.0002). The safety profiles of both vaccines were excellent. For HIV-1-infected individuals, no significant changes either in viremia or in the CD4+ cell count were observed at any time point. The results showed good safety and immunogenicity for both vaccines under study for both uninfected and HIV-1-infected adults, confirming current recommendations for immunization of this high-risk category.",
author = "P. Durando and D. Fenoglio and A. Boschini and F. Ansaldi and G. Icardi and L. Sticchi and A. Renzoni and P. Fabbri and A. Ferrera and A. Parodi and B. Bruzzone and G. Gabutti and A. Podda and {Del Giudice}, G. and E. Fragapane and F. Indiveri and P. Crovari and R. Gasparini",
year = "2008",
month = "2",
doi = "10.1128/CVI.00316-07",
language = "English",
volume = "15",
pages = "253--259",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults

AU - Durando, P.

AU - Fenoglio, D.

AU - Boschini, A.

AU - Ansaldi, F.

AU - Icardi, G.

AU - Sticchi, L.

AU - Renzoni, A.

AU - Fabbri, P.

AU - Ferrera, A.

AU - Parodi, A.

AU - Bruzzone, B.

AU - Gabutti, G.

AU - Podda, A.

AU - Del Giudice, G.

AU - Fragapane, E.

AU - Indiveri, F.

AU - Crovari, P.

AU - Gasparini, R.

PY - 2008/2

Y1 - 2008/2

N2 - The objective of this study was to evaluate and compare both the safety and tolerability and the humoral and cell-mediated immune responses for two influenza virus subunit vaccines, one with MF59 adjuvant (Fluad) and one without an adjuvant (Agrippal), in healthy and in human immunodeficiency virus type 1 (HIV-1)-infected adult individuals. To achieve this aim, an open, randomized, comparative clinical trial was performed during the 2005-2006 season. A total of 256 subjects were enrolled to receive one dose of vaccine intramuscularly. Blood samples were taken at the time of vaccination and at 1 and 3 months postvaccination. A good humoral antibody response was detected for both vaccines, meeting all the criteria of the Committee for Medical Products for Human Use. After Beyer's correction for prevaccination status, Fluad exhibited better immuno-genicity than Agrippal, as shown from the analysis of the geometric mean titers, with significant differences for some virus strains; however, no definitive conclusions on the clinical significance of such results can be drawn, because the method used to estimate antibody response is currently nonstandard for influenza virus vaccines. Significant induction of an antigen-specific CD4+ T-lymphocyte proliferative response was detected at all time points after immunization, for both the vaccines, among HIV-1-seronegative subjects. This was different from what was observed for HIV-1-infected individuals. In this group, significance was not reached at 30 days postvaccination (T30) for those immunized with Agrippal. Also when data were compared between treatment groups, a clear difference in the response at T30 was observed in favor of Fluad (P = 0.0002). The safety profiles of both vaccines were excellent. For HIV-1-infected individuals, no significant changes either in viremia or in the CD4+ cell count were observed at any time point. The results showed good safety and immunogenicity for both vaccines under study for both uninfected and HIV-1-infected adults, confirming current recommendations for immunization of this high-risk category.

AB - The objective of this study was to evaluate and compare both the safety and tolerability and the humoral and cell-mediated immune responses for two influenza virus subunit vaccines, one with MF59 adjuvant (Fluad) and one without an adjuvant (Agrippal), in healthy and in human immunodeficiency virus type 1 (HIV-1)-infected adult individuals. To achieve this aim, an open, randomized, comparative clinical trial was performed during the 2005-2006 season. A total of 256 subjects were enrolled to receive one dose of vaccine intramuscularly. Blood samples were taken at the time of vaccination and at 1 and 3 months postvaccination. A good humoral antibody response was detected for both vaccines, meeting all the criteria of the Committee for Medical Products for Human Use. After Beyer's correction for prevaccination status, Fluad exhibited better immuno-genicity than Agrippal, as shown from the analysis of the geometric mean titers, with significant differences for some virus strains; however, no definitive conclusions on the clinical significance of such results can be drawn, because the method used to estimate antibody response is currently nonstandard for influenza virus vaccines. Significant induction of an antigen-specific CD4+ T-lymphocyte proliferative response was detected at all time points after immunization, for both the vaccines, among HIV-1-seronegative subjects. This was different from what was observed for HIV-1-infected individuals. In this group, significance was not reached at 30 days postvaccination (T30) for those immunized with Agrippal. Also when data were compared between treatment groups, a clear difference in the response at T30 was observed in favor of Fluad (P = 0.0002). The safety profiles of both vaccines were excellent. For HIV-1-infected individuals, no significant changes either in viremia or in the CD4+ cell count were observed at any time point. The results showed good safety and immunogenicity for both vaccines under study for both uninfected and HIV-1-infected adults, confirming current recommendations for immunization of this high-risk category.

UR - http://www.scopus.com/inward/record.url?scp=40449113207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449113207&partnerID=8YFLogxK

U2 - 10.1128/CVI.00316-07

DO - 10.1128/CVI.00316-07

M3 - Article

C2 - 18003811

AN - SCOPUS:40449113207

VL - 15

SP - 253

EP - 259

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 2

ER -